People · Operator
Named in public records as an officer, director or promoter · active 2010–2022 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Allakos Inc. | — | Biotechnology | Series D+ | $128.1M | $4.1B | 2012 |
| OncoResponse Inc | — | Biotechnology | Series C | $109.0M | $39.3M | 2018 |
| Bonum Therapeutics, Inc. | — | Biotechnology | Series C | $46.2M | $746.1M | 2021 |
| Otonomy, Inc. | — | Biotechnology | Series B | $44.8M | $961.1M | 2010 |
| Adarza BioSystems, Inc. | — | Biotechnology | Series A | $31.5M | $461.9M | 2019 |
| Good Therapeutics, Inc. | — | Biotechnology | Series B | $31.1M | $188.6M | 2018 |
John McKearn at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside John McKearn on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| NICHOLAS WALROD | 2 | 8 |
| Mitchell Mutz | 2 | 5 |
| Karl Handelsman | 2 | 3 |
| Diane Hollenbaugh | 2 | 3 |
| John Mulligan | 2 | 3 |
| Neela Patel | 2 | 2 |
| Monique Schiersing | 2 | 2 |
| Steven Gillis | 1 | 23 |
| Wende Hutton | 1 | 16 |
| Andrew Perlman | 1 | 15 |
| Steve Gillis | 1 | 13 |
| Larry Page | 1 | 10 |
| Peter Bisgaard | 1 | 9 |
| Jeffrey Harris | 1 | 9 |
| David Weber | 1 | 8 |
| Jay Lichter | 1 | 7 |
| Brian Dovey | 1 | 7 |
| Geeta Vemuri | 1 | 7 |
| Jay Schmelter | 1 | 6 |
| Douglas Downs | 1 | 6 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.